

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1.-4. (Canceled)

5. (Currently Amended) A method for phosphorylating ~~a compound having a secondary hydroxyl group atorvastatin~~, the method comprising step (a) reacting the ~~compound having a secondary hydroxyl group atorvastatin~~ with P_4O_{10} in the presence of an alkali metal salt of a fatty acid.

6. (Canceled)

7. (Original) The method of claim 5 wherein the alkali metal salt of a fatty acid is sodium valerate.

8. (Original) The method according to claim 5 further comprising step (b) reacting the product of step (a) with a di or mono acyl glyceride to form a phosphatide.

9. (Currently Amended) The method according to claim 5 further comprising step (b') reacting the product of step (a) with a complexing agent ~~[[is]]~~ selected from the group comprising consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

10. (Currently Amended) The method according to claim 8 further comprising step (c) reacting the product of step (b) with a complexing agent ~~[[is]]~~ selected from the group

comprising consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

11. (Previously Presented) The method according to claim 9 wherein the complexing agent is selected from the group consisting of glycine, arginine, lysine, histidine and lauryl-imino-dipropionate.

12.-16. (Canceled)

17. (Previously Presented) The method according to claim 10 wherein the complexing agent is selected from the group consisting of glycine, arginine, lysine, histidine, and lauryl-imino-dipropionate.

18.-23. (Canceled)

24. (New) A phosphate derivative of atorvastatin made by the method of claim 5.

25. (New) A phosphate derivative of atorvastatin made by the method of claim 8.

26. (New) A phosphate derivative of atorvastatin made by the method of claim 9.

27. (New) A phosphate derivative of atorvastatin made by the method of claim 10.

28. (New) The phosphate derivative of claim 24, wherein the derivative is [R-(R*,R*)]-2-(4-fluorophenyl)- β -phosphono- δ -hydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino]carbonyl]-*lH*-pyrrole-1-heptanoic acid.

29. (New) The phosphate derivative of claim 25, wherein the derivative is 1,2-distearoyl phosphatidyl atorvastatin.

30. (New) A method of lowering serum cholesterol in a patient, the method comprising administering to the patient an amount of the phosphate derivative of claim 24 sufficient to lower the patient's serum cholesterol.

31. (New) A method of lowering serum cholesterol in a patient, the method comprising administering to the patient an amount of the phosphate derivative of claim 25 sufficient to lower the patient's serum cholesterol.

32. (New) A method of lowering serum cholesterol in a patient, the method comprising administering to the patient an amount of the phosphate derivative of claim 26 sufficient to lower the patient's serum cholesterol.

33. (New) A method of lowering serum cholesterol in a patient, the method comprising administering to the patient an amount of the phosphate derivative of claim 27 sufficient to lower the patient's serum cholesterol.